ERBB2 and metastatic neoplasm: The aforementioned DESTINY-PanTumor02 was an open-label, phase II study exploring the effectiveness of T-DXd (dosage of 5.4 mg/kg once every 3 weeks) among adults with HER2-expressing locally advanced, unresectable, or metastatic tumors with documented progression despite previous treatments or without alternative treatments.